EE344 Cost per Responder Associated with Bimekizumab Against Il-17A-Inhibitors in the Treatment of Axial Spondyloarthritis in Sweden
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.610
https://www.valueinhealthjournal.com/article/S1098-3015(23)03740-3/fulltext
Title :
EE344 Cost per Responder Associated with Bimekizumab Against Il-17A-Inhibitors in the Treatment of Axial Spondyloarthritis in Sweden
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03740-3&doi=10.1016/j.jval.2023.09.610
First page :
Section Title :
Open access? :
No
Section Order :
10099